Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method

Young‐Xu, Yinong; Snider, Julia Thornton; Aalst, Robertus van; Mahmud, Salaheddin M.; Thommes, Edward W.; Lee, Jason K H; Greenberg, David; Chit, Ayman

doi:10.1016/j.vaccine.2019.01.063

Cited by 31 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La rEV frente a hospitalizaciones por cualquier causa se estimó en el 10% (IC 95% 8 a 12%), frente a hospitalizaciones por eventos cardiorrespiratorios en el 18% (IC 95% 15 a 21%) y frente a hospitalizaciones por gripe o neumonía en el 14% (IC 95% 6 a 22%). El beneficio adicional de la vacuna de alta dosis se observó de forma similar en todas las temporadas analizadas [32] (tabla 2). Con este estudio se confirmaba la mayor efectividad de la vacuna de alta dosis previniendo hospitalizaciones por gripe durante 5 temporadas consecutivas, 2010-11 a 2014-15.…”

Section: Efectividad De La Vacuna Anti Gripal Trivalente De Alta Dosisunclassified

High-dose trivalent influenza vaccine. Efficacy and effectiveness

Miguel

Margüello²,

Díez-Domingo³

et al. 2020

Rev Esp Quimioter

View full text Add to dashboard Cite

Seasonal influenza is a major public health problem, particularly in older people. Influenza vaccine is the most effective way to prevent influenza virus infection and its complications, but due to immunosenescence, older people do not respond efficiently to immunization. In 2009, a high-dose trivalent influenza vaccine (IIV3-HD), containing four times more antigen than the standard-dose vaccine, was approved in the United States for the immunization of people aged 65 years and over. Numerous clinical trials, carried out at different seasons and using different methodologies, have shown that the IIV3-HD vaccine is, as well as safe, more immunogenic and more effective than the standard-dose vaccine in preventing influenza virus infection and its complications in older people. This paper reviews the available evidence on the efficacy and effectiveness of the IIV3-HD influenza vaccine in the elderly, with information from randomized clinical trials, as well as observational studies of real-world clinical practice and in systematic reviews/meta-analyses.

show abstract

Section: Efectividad De La Vacuna Anti Gripal Trivalente De Alta Dosisunclassified

High-dose trivalent influenza vaccine. Efficacy and effectiveness

Miguel

Margüello²,

Díez-Domingo³

et al. 2020

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

“…21 In an analysis of data collected from 1.7 million veterans over 5 influenza seasons, HD-IIV3 was shown to be more effective than IIVs in preventing influenza- or pneumonia-associated hospitalizations (rVE = 14%; 95% CI = 6-22), cardiorespiratory hospitalizations (rVE = 18%; 95% CI = 15-21), and all-cause hospitalization (rVE = 10%; 95% CI = 8-12). 22 Finally, in an analysis of data collected from 2.1 million members of a managed care company over 2 influenza seasons, HD-IIV3 was shown to be more effective than aIIV3 in preventing respiratory-related hospitalizations (rVE = 12%; 95% CI = 3.3-20). 23…”

Section: Clinical Trialsmentioning

confidence: 99%

“…There are no published studies on the relative vaccine effectiveness (rVE) of HD-IIV4 compared with other vaccines in adults aged 65 years and older in real-life, but data can be extrapolated from HD-IIV3. [19][20][21][22][23] In an analysis of data collected from 6.1 million Medicare beneficiaries over 2 influenza seasons, HD-IIV3 was shown to be more effective than IIVs in preventing postinfluenza deaths (rVE = 24.0%; 95% CI = 0.6-42). 19 In an analysis of data collected from a cohort of 73 773 veterans over 1 influenza season, HD-IIV3 was shown to be more effective than IIVs in preventing influenza-or pneumonia-associated hospitalization (rVE = 25%; 95% CI = 2-43) and all-cause outpatient visits (rVE = 5%; 95% CI = 2-8).…”

Section: Effectiveness Studiesmentioning

confidence: 99%

High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults

Chahine

2020

Ann Pharmacother

View full text Add to dashboard Cite

Objective: To review the efficacy and safety of the high-dose inactivated influenza vaccine quadrivalent (HD-IIV4) in the prevention of influenza in older adults. Data Sources: A literature search was performed using PubMed and Google Scholar with the search terms high-dose, influenza vaccine, and quadrivalent. Other resources included the Centers for Disease Control and Prevention (CDC), the prescribing information, and the manufacturer’s website. Study Selection and Data Extraction: All relevant English-language articles of studies assessing the efficacy and safety of HD-IIV4 were included. Data Synthesis: HD-IIV4 is licensed by the Food and Drug Administration for the prevention of influenza in adults aged 65 years and older. The safety and immunogenicity of HD-IIV4 was demonstrated in a phase 3 trial, and the efficacy of the trivalent formulation (HD-IIV3) was demonstrated in a phase 3b-4 trial. HD-IIV4 carries a warning regarding the occurrence of Guillain-Barré syndrome. Adverse reactions, including injection-site pain and myalgia, were reported more frequently with HD-IIV4 than with HD-IIV3. Relevance to Patient Care and Clinical Practice: Although the CDC recommends any age-appropriate influenza vaccine for adults aged 65 years and older, HD-IIV4 was associated with improved immunogenicity against the added B strain and HD-IIV3 provided better protection against influenza than the standard-dose vaccine. Other influenza vaccines have weaker evidence of efficacy in older adults. Therefore, HDIIV4 should be recommended as the vaccine of choice in adults aged 65 years and older. Conclusion: HD-IIV4 has proven immunogenic, safe, and effective in preventing influenza in older adults and should be recommended as the vaccine of choice in this patient population.

show abstract

“…14 These findings have been supported by post-marketing studies, which have shown that IIV3-HD provides improved protection against influenza, serious pneumonia, postinfluenza death, and all-cause, influenza-related, and cardiorespiratory-associated hospitalization. [15][16][17][18][19] To further improve protection against influenza in older adults, a quadrivalent formulation of the high-dose inactivated influenza vaccine (IIV4-HD) is being developed. A recent phase III trial in the US showed that, in healthy adults ≥65 years of age, IIV4-HD was well tolerated and induced immune responses that were non-inferior to responses induced by IIV3-HD for the shared strains and superior responses for the additional B-lineage strain.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

Sanchez¹,

Matsuoka

Inoue³

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in Japan, examined the safety and immunogenicity of a quadrivalent formulation of the high-dose inactivated influenza vaccine (IIV4-HD). Healthy adults ≥65 years of age were randomized to receive IIV4-HD by intramuscular injection (n = 60), IIV4-HD by subcutaneous injection (n = 60), or a quadrivalent standarddose inactivated influenza vaccine (IIV4-SD) by subcutaneous injection (n = 55). Irrespective of administration route, post-vaccination (day 28-35) hemagglutination inhibition geometric mean titers and seroconversion rates were higher for IIV4-HD than for IIV4-SD. Hemagglutination inhibition geometric mean titers and seroconversion rates were also higher for intramuscular than subcutaneous administration of IIV4-HD. Solicited reactions were more common in participants who received IIV4-HD administered subcutaneously than in those who received IIV4-HD administered intramuscularly or IIV4-SD administered subcutaneously. Unsolicited adverse events were similar between the vaccine groups, and no safety signals were detected. This study showed that IIV4-HD administered by either intramuscular or subcutaneous injection was well tolerated and highly immunogenic in healthy Japanese adults ≥65 years of age. Although this study was descriptive, the results add to the evidence that high-dose inactivated influenza vaccines are more immunogenic than standard-dose vaccines in this age group and that intramuscular administration provides greater immunogenicity and lower reactogenicity than subcutaneous administration.

show abstract

Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method

Cited by 31 publications

References 35 publications

High-dose trivalent influenza vaccine. Efficacy and effectiveness

High-dose trivalent influenza vaccine. Efficacy and effectiveness

High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

Contact Info

Product

Resources

About